Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters
Year: 2024
Type: article
Abstract: In the United States, Black people experience multiple myeloma (MM) at a frequency that is more than double that of White people and experience much higher rates of mortality. Despite bearing a disproportionate impact of both MM incidence and mortality, Black patients are significantly underrepresented in most MM clinical trials. This is in part because Black patients experience a higher prevalence of hemoglobinopathies and Duffy-null phenotype, which affect hemoglobin and neutrophil levels, respectively, potentially excluding patients from clinical trials. The Multiple Myeloma Research Foundation (MMRF) has convened a series of Health Equity Summits that include a focus on creating inclusive clinical trials for MM. The present paper, an output of the most recent workshop, focuses on the role of laboratory reference ranges as a barrier to clinical trial participation and offers tangible steps to improve the enrollment of a diverse and representative population.
Source: Seminars in Hematology
Institutions: Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Mass General Brigham, Brigham and Women's Hospital, The Barbara Ann Karmanos Cancer Institute, United States Food and Drug Administration, Center for Drug Evaluation and Research, Multiple Myeloma Research Foundation, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,910
OpenAlex ID: W4403777137